BMN 333

Peptide

Phase 2/3underway

Evidence outlook · registrational

Achondroplasia: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2029-06.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2/3 (1)
Achondroplasia

Competitive landscape

This drug's own stage for Achondroplasia: Phase 2/3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
BMN 333: this drugPhase 2/3PeptideC-type natriuretic peptide (CNP) pathwaynot yet gradedNo reviewed efficacy summary in this indication
Vosoritide (VOXZOGO)ApprovedPeptideNatriuretic peptide receptor B (NPR-B)Reliable signal
NCT03197766: Change From Baseline in Annualized Growth Velocity (AGV) at Week 52 (At Baseline and Week 52): BMN 111 - 15 μg/kg 1.71 cm/year (95% CI 1.4 to 2.01) | Placebo 0.13 cm/year (95% CI -0.18 to 0.45)
LavengratinibPhase 1/2Small moleculeFGFR2 / FGFR3not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow BMN 333 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
June 2029 (1)
Phase 2/3AchondroplasiaRecruiting
Est. primary completion 2029-06 · NCT07441876 · CT.gov ↗
What to watch

See the full readout calendar ↗